SOURCE: Micro Imaging Technology, Inc.

July 01, 2008 08:00 ET

Micro Imaging Technology, Inc. Retains Taglich Brothers, Inc. for Research and Analytical Coverage

SAN CLEMENTE, CA--(Marketwire - July 1, 2008) - Micro Imaging Technology, Inc. (OTCBB: MMTC), the supplier of a patented non-biological based system which can currently identify up to 23 species of bacteria in a matter of minutes at a cost of pennies per test, announced that it has retained Taglich Brothers, Inc. to provide research, analytical coverage and quarterly updates on the Company.

Taglich Brothers, Inc. (member NASD, SIPC) is a full service broker dealer focused exclusively on microcap companies, which is defined as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research to the investment community. More information on Taglich Brothers, including a recent research report on the Company, can be found by visiting or by calling (646) 290-5960.

Michael Brennan, Chairman of Micro Imaging Technology, Inc., stated, "Our Company is extremely pleased to have retained the services of such a high quality firm. The capabilities of Taglich Brothers will enhance the information stream provided to our shareholders and the investment community." Mr. Brennan further stated, "As the Company continues to grow, we are striving to provide a broader base of information for our investors and shareholders through a variety of independent research firms."

About Micro Imaging Technology:

The Company has developed and patented a technology for rapid microbe detection and identification. The MIT 1000 System measures scattered light intensity as individual microbes pass through a laser beam. The intensity pattern of the scattered light is a direct consequence of the size, shape and external and internal optical characteristics of the microbe. The MIT System is non-biological and does not rely on biological agents, conventional chemical processing, fluorescent tags, gas chromatography or DNA analysis.

MIT has demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, and other pathogenic bacteria. MIT recently performed over 300 tests for the identification the aforementioned contaminants and scored 95% accuracy. The System can currently identify 23 species of bacteria and is easily expandable. The identification process has been verified by North American Science Associates, Inc. (NAMSA), an independent, internationally recognized biological testing laboratory. The NAMSA Test Report, in the Company's opinion, demonstrated the accuracy, speed and efficiency of the MIT System over conventional processes and is available from the Company.

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission.

Contact Information

    Michael Brennan
    Email: Email Contact
    Telephone: (805) 557-0614